

The Boston University Biotech Group Presents: Life Science & Biotech Venture Capital for Patient Impact

**Emily Gaudiano, Ph.D.
MPM Capital Investment Team**



Emily Gaudiano was recently awarded her Ph.D. in Chemical Biology at Harvard Medical School under advisor Arlene Sharpe. Her thesis focused on characterizing novel signaling mechanisms of co-inhibitory receptor PD-1 in tumor infiltrating lymphocytes. In addition to her academic research, Emily served as a director on the leadership team of the GSAS Harvard Biotech Club and has been involved in a variety of community outreach programs across Boston to address healthcare disparities.

Now at MPM Capital, Dr. Gaudiano is responsible for investment identification, due diligence, business development, and company creation activities at MPM and BiolImpact Capital, an affiliate manager of MPM. Emily joined MPM full time in 2022 after completing an internship with the firm, where she supported diligence efforts for MPM newco Aktis Oncology and surveyed incoming deal flow for investment opportunities.

**BOSTON
UNIVERSITY
BIOTECH
GROUP**



**Boston University Center For Computing and Data Sciences (CCDS)
Room 1101, March 30, 3 - 4 P.M.**